|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC58 |
Gene summary for CCDC58 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC58 | Gene ID | 131076 |
| Gene name | mitochondrial matrix import factor 23 | |
| Gene Alias | CCDC58 | |
| Cytomap | 3q21.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q4VC31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 131076 | CCDC58 | LZE2T | Human | Esophagus | ESCC | 2.38e-03 | 8.29e-01 | 0.082 |
| 131076 | CCDC58 | LZE4T | Human | Esophagus | ESCC | 4.06e-11 | 4.43e-01 | 0.0811 |
| 131076 | CCDC58 | LZE7T | Human | Esophagus | ESCC | 1.07e-10 | 5.56e-01 | 0.0667 |
| 131076 | CCDC58 | LZE8T | Human | Esophagus | ESCC | 4.45e-03 | 1.69e-01 | 0.067 |
| 131076 | CCDC58 | LZE22T | Human | Esophagus | ESCC | 2.19e-06 | 3.51e-01 | 0.068 |
| 131076 | CCDC58 | LZE24T | Human | Esophagus | ESCC | 1.30e-08 | 2.60e-01 | 0.0596 |
| 131076 | CCDC58 | LZE21T | Human | Esophagus | ESCC | 9.13e-06 | 5.93e-01 | 0.0655 |
| 131076 | CCDC58 | P1T-E | Human | Esophagus | ESCC | 5.99e-08 | 4.62e-01 | 0.0875 |
| 131076 | CCDC58 | P2T-E | Human | Esophagus | ESCC | 3.30e-09 | 2.18e-01 | 0.1177 |
| 131076 | CCDC58 | P4T-E | Human | Esophagus | ESCC | 5.65e-31 | 9.10e-01 | 0.1323 |
| 131076 | CCDC58 | P5T-E | Human | Esophagus | ESCC | 1.56e-56 | 1.11e+00 | 0.1327 |
| 131076 | CCDC58 | P8T-E | Human | Esophagus | ESCC | 2.53e-19 | 3.37e-01 | 0.0889 |
| 131076 | CCDC58 | P9T-E | Human | Esophagus | ESCC | 4.22e-25 | 6.70e-01 | 0.1131 |
| 131076 | CCDC58 | P10T-E | Human | Esophagus | ESCC | 1.01e-48 | 7.44e-01 | 0.116 |
| 131076 | CCDC58 | P11T-E | Human | Esophagus | ESCC | 2.97e-04 | 2.99e-01 | 0.1426 |
| 131076 | CCDC58 | P12T-E | Human | Esophagus | ESCC | 1.22e-26 | 5.99e-01 | 0.1122 |
| 131076 | CCDC58 | P15T-E | Human | Esophagus | ESCC | 8.52e-23 | 4.80e-01 | 0.1149 |
| 131076 | CCDC58 | P16T-E | Human | Esophagus | ESCC | 5.09e-25 | 6.05e-01 | 0.1153 |
| 131076 | CCDC58 | P17T-E | Human | Esophagus | ESCC | 5.27e-05 | 4.58e-01 | 0.1278 |
| 131076 | CCDC58 | P19T-E | Human | Esophagus | ESCC | 1.62e-05 | 6.81e-01 | 0.1662 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC58 | SNV | Missense_Mutation | c.273N>C | p.Lys91Asn | p.K91N | Q4VC31 | protein_coding | tolerated(0.26) | benign(0.037) | TCGA-IR-A3LL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CCDC58 | SNV | Missense_Mutation | novel | c.250N>C | p.Asn84His | p.N84H | Q4VC31 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC58 | SNV | Missense_Mutation | c.273G>T | p.Lys91Asn | p.K91N | Q4VC31 | protein_coding | tolerated(0.26) | benign(0.037) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC58 | SNV | Missense_Mutation | novel | c.361N>A | p.Val121Met | p.V121M | Q4VC31 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC58 | SNV | Missense_Mutation | c.110N>T | p.Thr37Met | p.T37M | Q4VC31 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC58 | SNV | Missense_Mutation | novel | c.146C>T | p.Ala49Val | p.A49V | Q4VC31 | protein_coding | tolerated(0.08) | benign(0.311) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC58 | SNV | Missense_Mutation | novel | c.86N>T | p.Arg29Ile | p.R29I | Q4VC31 | protein_coding | deleterious(0.04) | probably_damaging(0.944) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCDC58 | SNV | Missense_Mutation | c.88N>C | p.Ile30Leu | p.I30L | Q4VC31 | protein_coding | deleterious(0.01) | possibly_damaging(0.871) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCDC58 | SNV | Missense_Mutation | c.110C>T | p.Thr37Met | p.T37M | Q4VC31 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| CCDC58 | SNV | Missense_Mutation | c.31N>C | p.Glu11Gln | p.E11Q | Q4VC31 | protein_coding | tolerated(0.47) | benign(0.287) | TCGA-B5-A11R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |